5 Best Stocks Under $5 This Week (BAMM, OHRP, BGMD, OGXI, OPGN)

Advertisement

It was an incredibly busy and nerve-wracking week for Wall Street, with Greece bailout votes, China government interventions, Fed interest-rate watches, and new second-quarter earnings reports all hitting the news wires simultaneously.

5 Best Stocks Under $5It was also a busy week for sub-$5 stocks, with the vast majority of the big percentage gainers again coming from the biotech and medical fields.

However, book retailer Books-A-Million (BAMM) made our list this week as well, so to honor that issue, we’re putting it first among the low-priced gems of the week:

Best Stocks Under $5: Books-A-Million (BAMM)

7/17/15 Closing Price: $3.18 (+23%)

Books-A-Million (BAMM), a retailer that has been floundering under the $5 mark since 2011, found a buyer this week — and right in its own backyard.

Chairman Clyde B. Anderson and an entity owned by other family members made an offer to purchase BAMM for $21 million, or $3.25 a share. On Jan. 29, the Anderson family made their initial proposal to buy the book retailer. At the time, the stock was selling for less than $2 a share. The board of directors formed an independent committee to study the purchase.

Nevertheless, several law firms are now investigating the sale, raising concerns about the fairness of the deal, with possible class action suits pending on the horizon.

You can make book on that!

Best Stocks Under $5: OHR Pharmaceutical (OHRP)

7/17/15 Closing Price: $3.68 (+62%)

OHR Pharmaceutical (OHRP) was the leading percentage gainer among sub-$5 stocks this week. The pharmaceutical company surged 65% after reporting strong data on its phase 2 study of Squalamine eye drops (OHR-102) (0.2% squalamine lactate ophthalmic solution), a treatment being evaluated for macular edema and several other back-of-the-eye diseases.

Brean Capital analyst Jonathan Aschoff is a huge fan of OHRP, and has put a “buy” rating on the stock with a target price of $34 — about 10 times its current price.

Best Stocks Under $5: BG Medicine, Inc. (BGMD)

7/17/15 Closing Price: $2.38 (+55.5%)

BG Medicine (BGMD) is a company that develops and delivers diagnostic solutions for the clinical management of heart failure and other heart-related conditions.

BGMD stock rose this week after announcing they have paid off a $10 million loan to General Electric Capital Corporation and Comerica Incorporated (CMA) that was taken out in 2012, and used to fund its medical development programs.

BG Medicine has developed the BGM Galectin-3 (R) test, a blood test to identify chronic heart failure patients who are at high risk for hospitalization or death.

BGMD was a $35 stock back in 2012.

Best Stocks Under $5: OncoGenex Pharmaceuticals (OGXI)

7/17/15 Closing Price: $2.72 (+22%)

It was a busy week for OncoGenex Pharmaceuticals (OGXI). On Monday, OGXI reported that its Phase 3 Enspirit trial to evaluate custirsen, a treatment for advanced non-small cell lung cancer, is continuing as planned.

This was important news because two interim analyses were planned to determine whether the treatments with custirsen should be halted. However, on the recommendation of an Independent Data Monitoring Committee, the decision to proceed was made. OGXI has made some improvements in their study, and has filed an amendment with the U.S. Food and Drug Administration to change the evaluation mechanisms to make them more rigorous.

Also this week, William Blair & Company LLC analyst Y. Katherine Xu maintained an “outperform” rating on OGXI stock, and raised her price target from $5 to $6.

Best Stocks Under $5: OpGen Inc (OPGN)

7/17/15 Closing Price: $4.15 (+21%)

OpGen Inc (OPGN) uses molecular testing and bioinformatics to combat multi-drug resistant bacterial infections.

This week, OPGN formed an affiliation with Fluidigm Corporation (NASDAQ:FLDM) to collaborate on developing test kits and other instruments to identify, screen and test multidrug-resistant organism genes of various bacteria, fungi and viruses.

The initial affiliation will last for five years, and has the potential to be extended for another five years thereafter. MDROs are common bacteria that have formed a resistance to many different types of commonly used antibiotics. The purpose of this collaboration is to be able to identify and treat asymptomatic carriers of MDROs in healthcare systems where the bacteria is dangerous and can easily be transmitted to other patients.

As of this writing, Ethan Roberts did not hold a position in any of the aforementioned securities.

More From InvestorPlace


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/5-best-stocks-5-bamm-ohrp-bgmd-ogxi-opgn/.

©2024 InvestorPlace Media, LLC